PerkinElmer Inc
LSE:0KHE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (417.9), the stock would be worth $108.25 (27% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 327.8 | $84.9 |
0%
|
| 3-Year Average | 417.9 | $108.25 |
+27%
|
| 5-Year Average | 407.2 | $105.49 |
+24%
|
| Industry Average | 5.1 | $1.31 |
-98%
|
| Country Average | 2.4 | $0.63 |
-99%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$1T
|
/ |
Dec 2025
$2.9B
|
= |
|
|
$1T
|
/ |
Dec 2025
$2.9B
|
= |
|
|
$1T
|
/ |
Dec 2026
$3B
|
= |
|
|
$1T
|
/ |
Dec 2027
$3.2B
|
= |
|
|
$1T
|
/ |
Dec 2028
$3.4B
|
= |
|
|
$1T
|
/ |
Dec 2029
$3.6B
|
= |
|
|
$1T
|
/ |
Dec 2030
$3.9B
|
= |
|
|
$1T
|
/ |
Dec 2031
$4.4B
|
= |
|
|
$1T
|
/ |
Dec 2032
$4.7B
|
= |
|
|
$1T
|
/ |
Dec 2033
$5.1B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 327.8 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
178B USD | 3.9 | 26 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.6B USD | 5.1 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 18.1 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
331.7B CNY | 7.2 | 17.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.5B CHF | 5 | -119.8 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 4.6 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.3B USD | 9.6 | 47.2 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.9B USD | 1.7 | 19.8 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26B USD | 6.5 | 29.9 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
21.1B USD | 6.6 | 38.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
PerkinElmer Inc
Glance View
PerkinElmer Inc., originally founded in 1937, has evolved over the decades into a leading global innovator in the field of healthcare and life sciences. It began its journey by focusing on precision optics, but with time, the company strategically pivoted towards life sciences, diagnostics, and applied markets. This transformation harnessed its focus on innovative technologies that aid in the process of scientific discovery and clinical diagnostics. PerkinElmer primarily thrives on providing advanced solutions for detecting and analyzing biological and chemical compounds. With its robust portfolio of products and services, the company empowers laboratories and research institutions worldwide to unlock new insights into areas such as genetics, oncology, and environmental health. The company's revenue streams are multifaceted, embodying a mix of instruments, software, and services that cater to a variety of needs in the scientific and healthcare communities. PerkinElmer’s business model is anchored on selling sophisticated laboratory equipment like mass spectrometers, imaging systems, and diagnostic testing kits. Beyond equipment sales, the company also capitalizes on recurring revenue from consumables and services, ensuring a steady cash flow that supports its ongoing R&D efforts and market expansion initiatives. Furthermore, with a strategic emphasis on bolstering partnerships and acquisitions, PerkinElmer continually enhances its capability to deliver comprehensive solutions, thus maintaining its competitive edge in the ever-evolving scientific landscape. Through this, it manages to contribute not just to profitability but to a broader mission of improving global health outcomes.
